Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
13.33
+0.04 (0.30%)
At close: Nov 21, 2024, 4:00 PM
13.45
+0.12 (0.90%)
After-hours: Nov 21, 2024, 4:47 PM EST

Company Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.

It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.

It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr.

Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr.

Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences.

The company was founded in 1781 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company logo
Country Japan
Founded 1781
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 49,281
CEO Christophe Weber

Contact Details

Address:
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku
Tokyo, 103-8668
Japan
Phone 81 3 3278-2111
Website takeda.com

Stock Details

Ticker Symbol TAK
Exchange NYSE
Fiscal Year April - March
Reporting Currency JPY
CIK Code 0001395064
CUSIP Number 874060205
ISIN Number US8740602052
SIC Code 2834

Key Executives

Name Position
Christophe Weber President, Chief Executive Officer and Representative Director
Dr. Seigo Izumo Chair of Management Board
Milano Furuta Chief Financial Officer and Director
Haruhiko Hirate Member of Management Board
Salvatore Alesci M.D., Ph.D. Member of Management Board and Head of Research & Development Global Science and Biomedical Policy
Norimasa Takeda Chief Accounting Officer and Corporate Controller
Iwaaki Taniguchi Senior Vice President of Corporate Finance and Controlling Department
Gabriele Ricci Chief Data and Technology Officer
Christopher David O'Reilly Global Head of Investor Relations and Global Finance
Yoshihiro Nakagawa Global General Counsel

Latest SEC Filings

Date Type Title
Oct 31, 2024 6-K Report of foreign issuer
Oct 31, 2024 6-K Report of foreign issuer
Oct 31, 2024 6-K Report of foreign issuer
Sep 26, 2024 6-K Report of foreign issuer
Aug 22, 2024 144 Filing
Jul 31, 2024 6-K Report of foreign issuer
Jul 10, 2024 144 Filing
Jul 10, 2024 144 Filing
Jul 10, 2024 144 Filing
Jul 10, 2024 144 Filing